Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

By sjmartinez • May 29, 2023

Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 Jun 13;7(11):2360-2363. doi: 10.1182/bloodadvances.2022008625. PMID: 36315007.

Tags: Hematology/Oncology, Publications

Related Posts

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im[...]

Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer

Chandrasekhar A, Yang HC, Demir T, Yeldandi A, Kurihara C, Tomic R, Gao R, Goldman JW, Nadig S, Chae YK, Bharat A. Multiorgan transplant for[...]

MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin

Fu X, Ma J, Ma F, Guo S, Wang X, Li Y, Tang Y, Qi J, Zhang W, Ye L. MISP-mediated enhancement of pancreatic cancer[...]